We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App





Carolina Liquid Chemistries Secures FDA Emergency Use Authorization for COVID-19 Test Kits

By LabMedica International staff writers
Posted on 31 Jul 2020
Print article
Image: DiaCarta RT-PCR QuantiVirus SARS-CoV-2 Test Kit (Photo courtesy of Carolina Liquid Chemistries, Corp.)
Image: DiaCarta RT-PCR QuantiVirus SARS-CoV-2 Test Kit (Photo courtesy of Carolina Liquid Chemistries, Corp.)
Carolina Liquid Chemistries, Corp. (CLC, Greensboro, NC, USA) has been granted FDA emergency use authorization for its COVID-19 test kits.

CLC’s COVID-19 test kits include two real-time reverse transcriptase polymerase chain reaction (RT-PCR) diagnostics, the DiaCarta RT-PCR QuantiVirus SARS-CoV-2 Test Kit and QuantiVirus SARS-CoV-2 Multiplex Test Kit. Both are intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasal swabs, nasopharyngeal swabs, oropharyngeal swabs, and sputum from individuals suspected of COVID-19.
New
Platinum Supplier
SARS-CoV-2/Influenza A & B/RSV Test
BIOSYNEX® AMPLIQUICK® SARS-COV-2 and Respiratory Triplex
New
POC Analyzer
Epithod 616
Visit expo >

The DiaCarta RT-PCR QuantiVirus SARS-CoV-2 Test Kit is based on Real-Time PCR technology, developed for specific detection of SARS-CoV-2 (COVID-19) viral RNA extracted from nasopharyngeal swabs, oropharyngeal swabs and sputum. The sensitivity is 100 copies per mL of SARS-CoV-2 viral with a 95% confidence. The assay is highly specific without cross-reaction with different types of non-SARS-CoV-2 species tested, and clinical validation shows 96.7% sensitivity and 100% specificity. Three genes of the SARS-CoV-2 including N, Orf1ab and E, are targeted in the qRT-PCR assay and primers and Taqman probes are designed in the conserved region of the SARS- CoV-2 virus-specific genome region to allow sensitive and specific amplification and detection of the virus. The human RNase P gene is used as internal and extraction control to monitor viral RNA extraction efficacy and assess amplifiable RNA/DNA in the samples to be tested.

The QuantiVirus SARS-CoV-2 Multiplex Test Kit is an enhanced throughput version of the QuantiVirus SARS-CoV-2 Test Kit. Based on real-time Reverse-Transcription Polymerase Chain Reaction (RT-PCR) technology, it is highly specific for the detection of SARS-CoV-2 (COVID-19) viral RNA extracted from nasopharyngeal swabs, oropharyngeal, and sputum samples. The level of detection is 50 copies per mL of SARS-CoV-2 viral load with a 95% confidence. Clinical validation of the assay shows 95% sensitivity and 100% specificity, with no cross-reaction to different types of non-SARS-CoV-2 species. The QuantiVirus SARS-CoV-2 Multiplex Test Kit combines four genes into one reaction well and increases throughput significantly to 93 samples in a 96 well plate or 381 samples in a 384 well plate.

“As case numbers have increased, so has demand for testing and the importance of trustworthy supply sources,” said CLC founder and CEO Philip Shugart. “Carolina Liquid Chemistries has been sourcing and manufacturing diagnostic test kits for over 25 years. It made sense for us to leverage our product sourcing capability to fill this need in the healthcare supply chain.”

Related Links:
Carolina Liquid Chemistries, Corp.


Print article

Channels

Molecular Diagnostics

view channel
Image: Histopathology of neurofibrillary tangles in the brain of a patient with Alzheimer`s disease (Bielschowski silver stain) (Photo courtesy of Dimitri P. Agamanolis, MD).

Alzheimer's Disease Subtypes Proposed from Brain Gene Expression Profiles

Alzheimer’s disease (AD) is the most common form of dementia in the elderly, estimated to affect more than 5.8 million individuals in the USA and more than 50 million worldwide, with almost half of individuals... Read more

Industry

view channel
Illustration

Thermo Fisher Acquires Point-of-Care Molecular Diagnostics Provider Mesa Biotech

Thermo Fisher Scientific Inc. (Waltham, MA, USA) has entered into a definitive agreement to acquire Mesa Biotech (San Diego, CA, USA), a privately held molecular diagnostic company, for approximately USD... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.